|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Labetalol#Drug Interactions]] |
| {{Labetalol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| In one survey, 2.3% of patients taking labetalol HCl in combination with[[ tricyclic antidepressants]] experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded.
| |
| | |
| Drugs possessing beta-blocking properties can blunt the [[bronchodilator]] effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of beta-agonist [[bronchodilator]] drugs may be required.
| |
| [[Cimetidine]] has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.
| |
| | |
| Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with [[halothane]], high concentrations (3% or above) of [[halothane]] should not be used because the degree of[[hypotension ]]will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl.
| |
| | |
| Labetalol HCl blunts the reflex [[tachycardia]] produced by [[nitroglycerin]] without preventing its [[hypotensive]] effect. If labetalol HCl is used with [[nitroglycerin]] in patients with [[angina]] pectoris, additional [[antihypertensive]] effects may occur.
| |
| | |
| Care should be taken if labetalol is used concomitantly with calcium antagonists of the [[verapamil]] type.
| |
| When drug products that are [[alkaline]], such as [[furosemide]], have been administered in combination with labetalol, a white precipitate has been noted. Therefore, these drugs should not be administered in the same infusion line.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LABETALOL HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abfc6b75-1ed5-41f1-0484-4597488237bc | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |